Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2014
At a glance
- Drugs Sagopilone (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Bayer added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History